AREDS2 Vitamins: Dosage, Indications, and Clinical Guidelines
The AREDS2 formulation (500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, 2 mg copper, 10 mg lutein, and 2 mg zeaxanthin) should be prescribed for patients with bilateral intermediate AMD or advanced AMD in one eye, as this reduces progression to late AMD by approximately 28%. 1, 2
Recommended Dosage
The evidence-based AREDS2 formulation consists of:
- Vitamin C: 500 mg
- Vitamin E: 400 IU
- Zinc: 25 mg (reduced from original 80 mg with equivalent efficacy)
- Copper: 2 mg (required to prevent copper-deficiency anemia when taking zinc)
- Lutein: 10 mg
- Zeaxanthin: 2 mg
- Beta-carotene: OMITTED (replaced with lutein/zeaxanthin due to lung cancer risk in smokers)
Specific Indications
Prescribe AREDS2 supplements for:
- Bilateral intermediate AMD (bilateral large drusen with or without pigment changes) - AREDS category 3
- Advanced AMD in one eye with intermediate AMD in the fellow eye - AREDS category 4
Do NOT prescribe for:
- Early AMD (small drusen only) - the absolute benefit is minimal (4 fewer cases per 1000 people)
- No AMD or minimal changes
- Pediatric patients (not studied)
Contraindications and Precautions
Absolute Contraindications
- Current smokers should NOT receive beta-carotene due to 28% increased relative risk of lung cancer (18% absolute difference in cumulative incidence). The AREDS2 formulation with lutein/zeaxanthin is appropriate for all patients including smokers. 1
Relative Contraindications and Monitoring Needs
Zinc-related concerns:
- History of recurrent genitourinary infections or hospitalizations (7.5% vs 4.9% hospitalization rate with 80 mg zinc)
- Prostatic hyperplasia in men
- Stress incontinence in women
- The 25 mg dose in AREDS2 shows no significant difference in AMD progression compared to 80 mg, with improved safety profile 1
Coordinate with primary care physician before initiating due to potential adverse effects and drug interactions, particularly in patients with:
- History of genitourinary conditions
- Multiple comorbidities
- Polypharmacy 1
Clinical Efficacy Data
For intermediate AMD patients (higher baseline risk):
- 78 fewer cases of late AMD per 1000 people treated (95% CI: 26-126 fewer)
- Neovascular AMD risk reduction: OR 0.62 (95% CI 0.47-0.82)
- Geographic atrophy risk reduction: OR 0.75 (95% CI 0.51-1.10)
- Visual acuity loss (≥3 lines) reduction: OR 0.77 (95% CI 0.62-0.96)
Lutein/zeaxanthin vs beta-carotene substitution showed hazard ratios of 0.82 for late AMD progression and 0.78 for neovascular AMD in exploratory analyses. 2
Monitoring Guidelines
Follow-up intervals per AMD severity (Table 4 reference from guidelines):
- Monitor for self-reported yellowing of skin (8.3% with antioxidants vs 6.0% without)
- Assess for genitourinary symptoms, particularly in men
- Screen for smoking status at every visit and actively promote cessation 1
At each follow-up visit:
- Distance visual acuity with correction
- Amsler grid testing
- Stereoscopic biomicroscopic fundus examination
- Assess compliance with supplementation
- Review changes in medications and medical history 1
Common Pitfalls
Major compliance issue: Only 60% of eligible patients take AREDS2 supplements, with 83% of non-compliant patients reporting they were never advised of the benefit. 4 Explicitly counsel patients on the evidence and expected benefit at diagnosis.
Formulation inconsistency: Commercial supplements marketed for "macular health" often deviate significantly from AREDS2 standards (vitamin C 52.3% lower, vitamin E 61.2% lower, zinc 40.1% lower on average). 5 Prescribe specific AREDS2-compliant formulations by name, not generic "eye vitamins."
Cost barrier: 10% of patients cite cost as reason for non-compliance. 4 Discuss this proactively and explore options.
Adverse Effects Profile
Common:
- Gastrointestinal symptoms (most frequent)
- Self-reported skin yellowing (8.3%)
Serious but preventable:
- Lung cancer with beta-carotene in smokers (use lutein/zeaxanthin instead)
- Copper-deficiency anemia (prevented by including 2 mg copper)
- Genitourinary hospitalizations with high-dose zinc (use 25 mg dose)
Mortality: No significant effect on all-cause mortality with multivitamin supplementation (HR 0.87,95% CI 0.60-1.25) or lutein/zeaxanthin (HR 1.06,95% CI 0.87-1.31). 2